此次调查恰逢加纳计划在2030年前逐步脱离全球疫苗免疫联盟的资助支持之际。调查于2月16日启动， 将于3月10日结束，覆盖全国16省的55个地区，面向11077名受访者收集数据，以评估公众对疫苗的信任 度，尤其是针对未来本土生产疫苗的接受态度。 厘清影响公众疫苗信任度的推动因素与接种阻碍，能帮助研究所及其合作方制定针对性策略。因为加纳 各地的疫苗接受度存在差异，加纳北部地区质疑情绪较为明显，而城市中心则主要面临虚假信息带来的 挑战。 （原标题：加纳启动全国疫苗调查，推进本土疫苗生产） 据"加纳时报"2月26日报道，加纳已启动一项全国性疫苗认知调查，由加纳国家疫苗研究所牵头开展， 作为本土疫苗生产筹备工作的重要组成部分。 ...

以上内容基于公开资料整理，不构成投资建议。 MACD金叉信号形成，这些股涨势不错！ 近期事件 2月24日A股节后首个交易日，疫苗板块整体表现疲软，行业深度调整因素包括HPV疫苗需求缩水、库 存积压等，金迪克作为相关企业受到拖累。同期医药板块内创新药、CXO等领域复苏，但疫苗细分赛 道承压明显。 经济观察网 根据21世纪经济报道2026年2月24日的分析，疫苗板块整体承压，金迪克在已披露2025年业 绩预告的疫苗企业中处于续亏状态。公司2025年1-9月营业收入为7465.76万元，同比增长91.93%，但归 母净利润为-8647.06万元，同比减少61.74%，反映业绩亏损压力。行业受接种意愿下降、需求疲软等因 素影响，金迪克作为疫苗企业面临调整期挑战。 股票近期走势 近一周金迪克股价呈现波动下跌趋势。2月26日股价单日下跌2.51%，报收19.45元，成交额1956.95万 元，主力资金净流出24.85万元。截至2月27日最新数据，股价微涨0.26%至19.50元，但近5日累计跌幅 为1.56%，年初至今下跌3.61%。融资余额连续下降，近5日减少0.06亿元，降幅18.62%，市场资金面偏 弱。 ...

2月26日，中慧生物发布盈喜公告：2025年，公司预计实现年度收入4.46亿元至4.93亿元，同比增长 71.8%至89.9%;公司预期当期将录得净亏损约1.57亿元至1.97亿元，同比显著收窄约23.9%至39.3%。 从二级市场角度来看，随着中慧生物被纳入新一轮港股通标的名单，市场对公司的关注度出现明显提 升。智通财经APP观察到，今年1月，国海证券发布研报首次覆盖中慧生物，给予公司"增持"评级;而在 股价层面，在去年股价累涨逾200%后，中慧生物股价今年年初至今的上涨幅度再超30%，反映出场内 持续高涨的交投热情以及投资者对公司长期价值的认可。 而此次中慧生物披露年度业绩盈喜，进一步提高了公司长期增长确定性，表明公司在专注创新疫苗升级 的同时，已进入商业化兑现期，有望迎来业绩与估值双重提升的"戴维斯双击"。 商业化能力再获验证，"投资确定性"进一步提升 今年以来，中慧生物股价走出一段"小高潮"，最高股价达到59.90港元，较公司上市发行价上涨逾 360%，但该表现本质上体现的是中慧生物深耕创新疫苗战略下的阶段性成果。而其中的关键载体，便 是逐渐获得商业化验证的核心品种——四价流感病毒亚单位疫苗慧尔康欣® ...

继今年1月30日宣布公司自主研发的全国首款且唯一的全人群三价流感病毒亚单位疫苗成功获批上市 后，中慧生物-B(02627)近日再传重磅利好。 自2023年9月上市以来，慧尔康欣便凭借自身优异的安全性与免疫原性，始终保持了100%的产品批签发 合格率，并实现了销售网络快速扩张，目前该产品已覆盖国内30个省份、增加覆盖了232个疾控中心以 及2563个接种门诊。而在市场准入与支付端，公司也取得积极进展：该疫苗已通过2025年国家商业健康 保险创新药品目录初步审查，有望进一步加速在公立市场及商业保险渠道的渗透。 根据盈喜公告，报告期内，中慧生物收入同比大幅增长71.8%至89.9%，说明作为公司当前核心收入来 源，慧尔康欣的显著临床价值和产品力获得了终端市场的持续高度认可。 之所以说公司投资确定性正进一步提升，背后的直接原因在于中慧生物已来到一个全年利润转正、创新 商业化品种加速兑现的关键转折点。 首先，对于公司首款商业化品种慧尔康欣而言，公司正持续深化其核心产品价值，积极拓展适用人群。 在已覆盖6月龄以上全人群基础上，针对65岁及以上老年人的佐剂型疫苗已获临床批件，通过添加佐剂 增强老年人群免疫应答;针对孕妇群体 ...

美国疾控中心1月5日发布备忘录，宣布不再将7种儿童疫苗列为"普遍推荐接种"疫苗。这些疫苗针 对轮状病毒、脑膜炎、甲肝、乙肝、流感、新冠和呼吸道合胞病毒。 邦塔批评疾控中心的决定"不负责且危险"。"削弱民众对疫苗的信心将导致接种率下降、传染病增 多，还会推高各州开支，包括医疗补助支出增加、新增用于辟谣和修订公共卫生指引的开支。" 肯尼迪2025年初受美国共和党籍总统特朗普任命正式出任卫生与公共服务部长。他曾多次发表反疫 苗言论，批评疾控中心等联邦卫生机构及其防疫措施，同时大幅裁减下属机构人员和经费，招致公共卫 生界广泛质疑。 新华社北京2月25日电 美国加利福尼亚州总检察长罗布·邦塔和亚利桑那州总检察长克丽丝·梅斯24 日宣布牵头一起由15个州参与的诉讼，指控联邦政府削减儿童疫苗接种计划违法，会增加疾病风险并使 各州不堪重负。这些州均为民主党人主政。 邦塔和梅斯等14州总检察长以及宾夕法尼亚州州长乔希·夏皮罗参与诉讼。他们在加州北区联邦地 区法院提交诉状，将美国卫生与公共服务部长小罗伯特·肯尼迪、疾病控制和预防中心代理主任杰伊·巴 塔查里亚以及两人所属机构列为被告。 据法新社24日报道，特朗普政府1月曾以其他国 ...

"我买了点医药ETF，从2025年年中慢慢加仓到现在差不多1万元，期待马年创新药还有一波春季行情"，90后小宇（化名）告诉 21世纪经济报道记者。 另一位95后投资者天天（化名）则告诉21世纪经济报道记者，相比传统的制药概念股，"我更看重有消费属性的医疗服务概念， 跟爱尔眼科看眼睛、通策医疗看牙齿是一个道理，毕竟这些刚需还在"。 在投资社区上，不乏网友分享投资医药股的心路历程，"恒瑞医药持有了三年，之前一直处于亏损状态，持有成本58元，漫长的 亏损期真的让人无比难受，但是买入以后没有做任何动作，（2025年）终于等到了盈利的一天"。 随着不少创新药、CXO、高端医疗器械等药企的确定性业绩，助推细分赛道获得市场追捧。 Wind数据显示，截至2026年1月31日，共有283只医药股披露了2025年业绩预告。按预告归母净利润上限看，有160只个股归母净 利润同比增长，占比超五成，释放积极信号，尤其是创新药、CXO、高端医疗器械等细分赛道各有亮点。 在核心产品商业化放量驱动下，不少创新药企从"投入期"步入"收获期"，业绩确定性逐步获得财报验证。 例如，老牌ADC药企荣昌生物预计2025年归母净利润约7.16亿元，而上 ...

Core Viewpoint - Shenzhen Kangtai Biological Products Co., Ltd. has announced the termination of its plan to establish a vaccine joint venture with AstraZeneca Investment (China) Co., Ltd., highlighting the company's strategic challenges amid a declining vaccine industry and significant performance downturn [1][6]. Group 1: Strategic Instability and Execution Doubts - The collaboration with AstraZeneca was seen as a crucial step in the company's "external expansion" strategy, aimed at leveraging the strength of an international pharmaceutical company to expand its vaccine business [2][7]. - The termination of this partnership within a year is attributed to "dramatic changes in the market environment," marking the second major strategic adjustment for the company in recent times [2][7]. - Last year, the company also halted the development of an inactivated vaccine for the original strain of the COVID-19 virus, citing reduced economic and social benefits, indicating potential gaps in strategic planning and execution [2][7]. Group 2: Core Product Pressure and Profit Decline - The company stated that the termination of the joint venture would not significantly impact its operations; however, recent performance indicators reveal underlying pressures [3][8]. - According to a performance forecast released on January 29, the company expects its net profit attributable to shareholders to decline by 63.80% to 75.70% year-on-year for 2025, with non-recurring net profit expected to drop by 68.90% to 79.06% [3][8]. - The decline is primarily due to the impact of adjustments in immunization programs on its main product, the "four-in-one vaccine," along with rising operating costs and increased R&D investments [3][8]. Group 3: Dual Challenges Amid Industry Changes - The global vaccine industry is transitioning from a high-growth phase during the pandemic to a normalization phase, characterized by intensified competition, price pressures, and extended R&D return cycles [4][9]. - The company's recent strategic pullbacks can be viewed as a defensive measure, yet they also reveal its passive position during this industry transformation [4][9]. - The company aims to drive internationalization through a dual approach of "internal innovation + external expansion," but faces obstacles in external collaborations while its core products are squeezed by policy and cost pressures [4][9]. Conclusion - The termination of the partnership with AstraZeneca, the cessation of COVID-19 vaccine development, and the significant profit reduction reflect a challenging period for the company [5][10]. - In the context of an overall industry adjustment, the company needs to reassess its strategic pace, product structure, and risk resilience to avoid losing initiative during industry reshuffling [5][10]. - The ability to achieve a stable transformation through the "dual-driven" approach remains to be tested by the market and time [5][10].

Core Viewpoint - The approval of a high-dose influenza virus split vaccine by Chengda Biological's subsidiary marks a significant step in addressing the growing demand for influenza prevention among the aging population in China [1][2] Group 1: Vaccine Approval and Characteristics - Chengda Biological's high-dose influenza virus split vaccine has received approval from the National Medical Products Administration to conduct clinical trials [1] - The vaccine is developed using WHO-recommended strains and has an antigen content four times that of standard-dose influenza vaccines, targeting individuals aged 60 and above [1] Group 2: Market Context and Implications - The aging population in China is increasing, leading to a heightened demand for effective influenza prevention strategies among the elderly [2] - Currently, there are no high-dose influenza vaccines approved for sale in China, making this clinical trial approval a crucial step for the company in responding to health aging strategies [2] Group 3: Future Development and Strategic Goals - Chengda Biological aims to continue its innovation-driven development strategy, enhancing its technological platform and the ability to translate research outcomes into products [2] - The company plans to advance the research and development of influenza vaccines and other key projects to improve public health and contribute to the high-quality development of China's biopharmaceutical industry [2]

股价方面，万泰生物近期表现疲软，截至2026年2月11日收盘报41.34元，年初至今累计下跌8.01%。成 交金额萎缩，市场交投清淡，资金流向显示主力资金净流出。 经济观察网近期，万泰生物（603392）董事长邱子欣计划减持不超过500万股股份，同时公司实际控制 人钟睒睒辞任董事长，由邱子欣接任，引发投资者对公司战略稳定性的担忧。此外，疫苗行业面临业绩 压力，万泰生物作为HPV疫苗龙头受集采降价和竞争加剧影响。 股票近期走势 机构对万泰生物评级偏中性，盈利预测显示2025年净利润预计增长，但当前市盈率为负值。市场关注九 价疫苗放量进度及减持计划对股价的潜在压力。 以上内容基于公开资料整理，不构成投资建议。 机构观点 ...

Core Viewpoint - The collaboration between Kangtai Biological and AstraZeneca has ended, reflecting the significant challenges and structural issues facing the vaccine industry in China, particularly in light of changing market conditions and increased investment risks [1][2]. Group 1: Collaboration and Market Changes - Kangtai Biological and AstraZeneca established a strategic partnership in March 2025, with a total investment of approximately $400 million, each holding a 50% stake in a joint venture [1]. - On February 6, 2026, Kangtai announced the termination of its collaboration with AstraZeneca due to drastic changes in the market environment and significant downward pressure on the vaccine industry [1]. Group 2: Industry Performance and Financial Struggles - The year 2025 marked a downturn for the Chinese vaccine industry, with major players facing significant financial pressure; Kangtai's net profit is projected to decline by 63.8% to 75.7%, amounting to only 49 million to 73 million yuan [2]. - Zhifei Biological, once a leading company, is expected to report a net loss of 10.698 billion to 13.726 billion yuan for the first time since its listing, far exceeding market expectations [2]. - Watson Bio's revenue is projected to be around 2.4 billion yuan, a 14% decline year-on-year, with net profit dropping by 9% to 22% [2]. Group 3: Clinical Trials and Financial Issues - Kanglao Health has faced severe financial issues, leading to the suspension of clinical trials for its HPV vaccines due to overdue payments and funding shortages [3]. - The company has previously defaulted on a bank loan of 15.21 million yuan, resulting in account freezes, highlighting ongoing financial instability [3]. Group 4: Market Demand and Competitive Pressure - Kangtai's declining performance is attributed to changes in the immunization schedule for the DTP vaccine, which negatively impacted the uptake of its four-component vaccine [4][5]. - The HPV vaccine market has seen a decrease in demand due to economic cycles and increased competition, leading to price wars among numerous entrants [6]. Group 5: Industry Challenges and Future Outlook - The vaccine industry is currently facing significant internal competition and structural challenges following a period of rapid expansion [7]. - The historical weaknesses in China's vaccine industry have led to a situation where many companies are now struggling to maintain profitability amidst increased competition and changing market dynamics [8].